Compare Check Point Software Technologies Ltd (CHKP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Sana Biotechnology Inc — how do they compare? Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Check Point Software Technologies Ltd is far larger — about 11.7× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | SANA | |
|---|---|---|
Market Cap | $13.18B | $1.13B |
Sector | Technology | Health |
52-Week High | $206.91 | $5.92 |
52-Week Low | $112.47 | $2.68 |
Enterprise Value | $12.88B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
